Centient Biotech Investor submits: InterMune (ITMN) scaled back its operations, two weeks after Actimmune failed a Phase III test for idiopathic pulmonary fibrosis. Actimmune is approved for two indications, both of which have small patient populations. The company believes that most of its Actimmune revenue came from off-label use for IPF, which will now stop. >>> Discuss This Story
